Type 1 Diabetes and Depression: Role of Brain Glutamate
NCT05355285, Not applicable, Completed, Beth Israel Deaconess Medical Center
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Type 1 Diabetes and Depression: Role of Brain Glutamate | ClinicalTrials.gov |
| NCT number | NCT05355285 | ClinicalTrials.gov |
| Status | Completed | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 68 participants, actual | ClinicalTrials.gov |
| Lead sponsor | Beth Israel Deaconess Medical Center | ClinicalTrials.gov |
| Conditions | Type1diabetes, Depressive Symptoms, Major Depressive Disorder | ClinicalTrials.gov |
| Interventions | Glucose Clamp | ClinicalTrials.gov |
| First posted | 2022-05-02 | ClinicalTrials.gov |
| Last updated | 2022-05-05 | ClinicalTrials.gov |
Registered outcomes 25
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Anterior cingulate cortex glutamate concentration during Baseline Euglycemia | Baseline Euglycemia | mmol/kg wet weight of brain tissue | ClinicalTrials.gov |
| Primary | Change in anterior cingulate cortex glutamate concentration from Baseline Euglycemia to Hyperglycemia | During the MRI scanning visit with hyperglycemic clamp, up to 180 minutes | mmol/kg wet weight of brain tissue | ClinicalTrials.gov |
| Secondary | Change in anterior cingulate cortex glutamate concentration from Baseline Euglycemia to Hyperinsulinemic Euglycemia | During the MRI scanning visit with hyperinsulinemic euglycemic clamp, up to 180 minutes | mmol/kg wet weight of brain tissue | ClinicalTrials.gov |
| Secondary | Change in occipital lobe glutamate concentration from Baseline Euglycemia to Hyperglycemia | During the MRI scanning visit with hyperglycemic clamp, up to 180 minutes | mmol/kg wet weight of brain tissue | ClinicalTrials.gov |
| Secondary | Change in occipital lobe glutamate concentration from Baseline Euglycemia to Hyperinsulinemic Euglycemia | During the MRI scanning visit with hyperinsulinemic euglycemic clamp, up to 180 minutes | mmol/kg wet weight of brain tissue | ClinicalTrials.gov |
| Secondary | Change in anterior cingulate cortex myo-inositol concentration from Baseline Euglycemia to Hyperglycemia | During the MRI scanning visit with hyperglycemic clamp, up to 180 minutes | mmol/kg wet weight of brain tissue | ClinicalTrials.gov |
| Secondary | Change in anterior cingulate cortex myo-inositol concentration from Baseline Euglycemia to Hyperinsulinemic Euglycemia | During the MRI scanning visit with hyperinsulinemic euglycemic clamp, up to 180 minutes | mmol/kg wet weight of brain tissue | ClinicalTrials.gov |
| Secondary | Change in occipital lobe myo-inositol concentration from Baseline Euglycemia to Hyperglycemia | During the MRI scanning visit with hyperglycemic clamp, up to 180 minutes | mmol/kg wet weight of brain tissue | ClinicalTrials.gov |
| Secondary | Change in occipital lobe myo-inositol concentration from Baseline Euglycemia to Hyperinsulinemic Euglycemia | During the MRI scanning visit with hyperinsulinemic euglycemic clamp, up to 180 minutes | mmol/kg wet weight of brain tissue | ClinicalTrials.gov |
| Secondary | Change in Intrinsic Neuronal Activity from Baseline Euglycemia to Hyperglycemia | During the MRI scanning visit with hyperglycemic clamp, up to 180 minutes | Fractional amplitude of low frequency fluctuations (fALFF) of fMRI signal | ClinicalTrials.gov |
| Secondary | Change in Intrinsic Neuronal Activity from Baseline Euglycemia to Hyperinsulinemic Euglycemia | During the MRI scanning visit with hyperinsulinemic euglycemic clamp, up to 180 minutes | Fractional amplitude of low frequency fluctuations (fALFF) of fMRI signal | ClinicalTrials.gov |
| Secondary | Change in Functional Connectivity from Baseline Euglycemia to Hyperglycemia | During the MRI scanning visit with hyperglycemic clamp, up to 180 minutes | Correlation strength of fMRI signal fluctuations between brain regions | ClinicalTrials.gov |
| Secondary | Change in Functional Connectivity from Baseline Euglycemia to Hyperinsulinemic Euglycemia | During the MRI scanning visit with hyperinsulinemic euglycemic clamp, up to 180 minutes | Correlation strength of fMRI signal fluctuations between brain regions | ClinicalTrials.gov |
| Secondary | Change in plasma glucose concentration from Baseline Euglycemia to Hyperglycemia | During the MRI scanning visit with hyperglycemic clamp, up to 180 minutes | mmol/L | ClinicalTrials.gov |
| Secondary | Change in plasma glucose concentration from Baseline Euglycemia to Hyperinsulinemic Euglycemia | During the MRI scanning visit with hyperinsulinemic euglycemic clamp, up to 180 minutes | mmol/L | ClinicalTrials.gov |
| Secondary | Change in plasma insulin concentration from Baseline Euglycemia to Hyperglycemia | During the MRI scanning visit with hyperglycemic clamp, up to 180 minutes | micro-Unit/mL | ClinicalTrials.gov |
| Secondary | Change in plasma insulin concentration from Baseline Euglycemia to Hyperinsulinemic Euglycemia | During the MRI scanning visit with hyperinsulinemic euglycemic clamp, up to 180 minutes | micro-Unit/mL | ClinicalTrials.gov |
| Other | Hamilton Depression rating (HAM-D) | Baseline | Hamilton depression rating Score from 0 to 51. Higher scores indicate worse depression. | ClinicalTrials.gov |
| Other | Revised Symptom Checklist rating (SCL-90-R) | Baseline | Revised Symptom Checklist rating Score from 0 to 360. Higher scores indicate worse symptoms. | ClinicalTrials.gov |
| Other | Wechsler Abbreviated Scale of Intelligence - intelligence quotient (WASI-IQ) | Baseline | Wechsler Abbreviated Scale of Intelligence - intelligence quotient Score from 40 to 160 (mean = 100, standard deviation = 15). Higher scores indicate better intellectual ability. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 2
The papers the trial lists on ClinicalTrials.gov.
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 2
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Emotional Stroop Task | Other outcome | ConductCognition |
| Stroop Color-Word Test | Other outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)